Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.
Topic summary
What changed in 2026, by region — does this still hold?
This is a generated summary. It shows the 5 most-liked posts from a topic of 26, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
I read post #5 twice before replying, because I had assumed the opposite.
Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.
25 likes 3mo
post #9 answers the question as asked. The question underneath it is different.
Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.
26 likes 2mo
n.villalobos, post #4: Picking up the opening post: that is the part I would want checked first. Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent. Go to post
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
Read the full topic (26 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Prescription portability between countries
Prescription portability between countries — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…
|
+104 | 114 | 6.1k | 3h |
|
Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+72 | 81 | 6.9k | 8mo |
|
Cross-border purchase within the EU: the actual rules
Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is…
|
+6 | 10 | 41k | 11mo |
|
Personal import allowances, compared
On the subject in the title: Personal import allowances, compared Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of July 2026, in…
|
+5 | 9 | 3.2k | 7mo |
|
Prescription portability between countries — the long version
On the subject in the title: Prescription portability between countries — the long version Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
|
2 | 182 | 21h |
Related topics — sharing the tags personal import, MHRA, EMA
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] EU-wide position versus national implementation
On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…
|
2 | 54k | 19mo | |
|
What a regulator's shortage notice actually authorises
What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. A logistics question, since the answers here are usually better…
|
+8 | 12 | 15k | 17h |
|
Pharmaceutical compounding rules, summarised from primary sources — a second dataset
Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. A logistics question, since the…
|
+50 | 56 | 780 | 8mo |
|
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Documenting an access outcome, dated, because…
|
+127 | 150 | 41k | 20mo |
|
NHS criteria and how they are applied in practice — the long version
Posting this under the heading it deserves: NHS criteria and how they are applied in practice — the long version Everything below is what sits behind that. A coverage question with the paperwork detail…
|
+11 | 15 | 11k | 9mo |